Nurix Therapeutics (NRIX) Price & Analysis

Compare

483 Followers

NRIX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$8.18 - $29.56

Previous CloseN/A

Volume302.00K

Average Volume (3M)1.17M

Market Cap

$750.38M

Enterprise Value$413.71M

Total Cash (Recent Filing)$428.83M

Total Debt (Recent Filing)$56.49M

Price to Earnings (P/E)―

Beta2.15

Next Earnings

Feb 18, 2026

EPS Estimate

-1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.03

Shares Outstanding76,883,440

10 Day Avg. Volume1,297,275

30 Day Avg. Volume1,168,880

Financial Highlights & Ratios

PEG Ratio-0.88

Price to Book (P/B)2.82

Price to Sales (P/S)27.21

P/FCF Ratio-8.16

Enterprise Value/Market Cap0.55

Enterprise Value/Revenue4.94

Enterprise Value/Gross Profit5.26

Enterprise Value/Ebitda-1.74

Forecast

1Y Price Target

$26.67

Price Target Upside173.26% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentsThe presentation of updated/incremental P1 bexobrutideg dose-escalation/expansion data at ASH is expected to be a key catalyst, offering better insights into competitive positioning, especially regarding durability.

Financial PerformanceNurix reported $44.1M in collaboration/license revenue, exceeding previous estimates of $25.0M.

Strategic DevelopmentsManagement formally announced plans to initiate a P2 single-arm trial evaluating single-agent bexdeg in relapsed/refractory CLL/SLL patients, which could lead to accelerated approval.

Bears Say

Competitive ChallengesThe stock is not expected to perform well until there is clinical differentiation versus BGB-16673, clarity on a time- and capital-efficient development path, and/or a value-driving strategic partnership.

Financial LossThe GAAP net loss of $86M was wider than expected and revenue was lower than anticipated, primarily due to decreased collaboration revenue from SNY.

Increased ExpensesNRIX noted an increase in spending in preparation for these pivotal studies, leading to a raise in R&D expense assumptions.

Nurix Therapeutics News

Nurix Therapeutics price target lowered to $22 from $25 at Wells Fargo

Wells Fargo lowered the firm’s price target on Nurix Therapeutics (NRIX) to $22 from $25 and keeps an...

22h ago

KYMR

NRIX

Nurix Therapeutics price target lowered to $33 from $35 at Stifel

Stifel lowered the firm’s price target on Nurix Therapeutics (NRIX) to $33 from $35 and keeps a Buy...

4d ago

NRIX

3 Best Stocks to Buy Now, 10/10/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

4d ago

IVA

CABA

Nurix Therapeutics price target lowered to $28 from $30 at Oppenheimer

Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Nurix Therapeutics (NRIX) to $28 from $30 and...

4d ago

NRIX

Nurix Therapeutics price target lowered to $32 from $35 at Piper Sandler

Piper Sandler lowered the firm’s price target on Nurix Therapeutics (NRIX) to $32 from $35 and keeps an...

4d ago

NRIX

Nurix Therapeutics price target lowered to $28 from $30 at Oppenheimer

Oppenheimer lowered the firm’s price target on Nurix Therapeutics (NRIX) to $28 from $30 but keeps an Outperform...

4d ago

NRIX

Closing Bell Movers: Levi Strauss down 8% after results

Major U.S. indices were down on Thursday despite constructive pre-market results from S&P 500 components Delta Airlines (DAL)...

4d ago

DAL

Nurix Therapeutics reports Q3 EPS ($1.03), consensus (85c)

Reports Q3 revenue $7.89M, consensus $16.06M. “Nurix is preparing to initiate pivotal studies for bexobrutideg in relapsed/refractory CLL...

5d ago

NRIX

Nurix Therapeutics presents data from GS-6791

Nurix Therapeutics (NRIX) announced the presentation of preclinical data from GS-6791/NX-0479, a novel IRAK4 protein degrader discovered as...

27d ago

GILD

NRIX

Nurix Therapeutics Reports Increased Losses Amid R&D Expansion

Nurix Therapeutics, Inc. ( ($NRIX) ) has released its Q3 earnings. Here is a breakdown of the information...

6h ago

NRIX

Nurix Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating

Needham analyst Gil Blum has maintained their bullish stance on NRIX stock, giving a Buy rating yesterday. Gil...

4d ago

NRIX

NRIX Upcoming Earnings Report: What to Expect?

Nurix Therapeutics, Inc. (NRIX) is scheduled to report 3rd quarter earnings on 10/09/2025. Regarding Q3 estimates, Wall Street...

7d ago

NRIX

Nurix Therapeutics to Discuss Bexobrutideg Developments

Nurix Therapeutics ( ($NRIX) ) has issued an update. Nurix Therapeutics announced plans to meet with securities analysts...

1M ago

NRIX

Nurix Therapeutics Announces Leadership Change in Committee

Nurix Therapeutics ( ($NRIX) ) has provided an announcement. On August 19, 2025, Nurix Therapeutics announced that Lori...

2M ago

NRIX

NRIX FAQ

What was Nurix Therapeutics’s price range in the past 12 months?

Nurix Therapeutics lowest stock price was $8.18 and its highest was $29.56 in the past 12 months.

What is Nurix Therapeutics’s market cap?

Nurix Therapeutics’s market cap is $750.38M.

When is Nurix Therapeutics’s upcoming earnings report date?

Nurix Therapeutics’s upcoming earnings report date is Feb 18, 2026 which is in 127 days.

How were Nurix Therapeutics’s earnings last quarter?

Nurix Therapeutics released its earnings results on Oct 09, 2025. The company reported -$1.03 earnings per share for the quarter, missing the consensus estimate of -$0.817 by -$0.213.

Is Nurix Therapeutics overvalued?

According to Wall Street analysts Nurix Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nurix Therapeutics pay dividends?

Nurix Therapeutics does not currently pay dividends.

What is Nurix Therapeutics’s EPS estimate?

Nurix Therapeutics’s EPS estimate is -1.

How many shares outstanding does Nurix Therapeutics have?

Nurix Therapeutics has 76,883,440 shares outstanding.

What happened to Nurix Therapeutics’s price movement after its last earnings report?

Nurix Therapeutics reported an EPS of -$1.03 in its last earnings report, missing expectations of -$0.817. Following the earnings report the stock price went up 8.818%.

Which hedge fund is a major shareholder of Nurix Therapeutics?

Currently, no hedge funds are holding shares in NRIX

Nurix Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-65.35%

Trailing 12-Months

Asset Growth

1.73%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nurix Therapeutics

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

Nurix Therapeutics (NRIX) Earnings & Revenues

Historic Earnings Reports

NRIX Stock 12 Month Forecast

Average Price Target

$26.67

▲(173.26% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","35":"$35","14.75":"$14.75","21.5":"$21.5","28.25":"$28.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,14.75,21.5,28.25,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.4,11.292307692307693,13.184615384615386,15.076923076923077,16.96923076923077,18.861538461538462,20.753846153846155,22.646153846153847,24.53846153846154,26.43076923076923,28.323076923076925,30.215384615384615,32.10769230769231,{"y":34,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.4,10.72846153846154,12.056923076923077,13.385384615384616,14.713846153846156,16.042307692307695,17.370769230769234,18.699230769230773,20.027692307692313,21.356153846153852,22.68461538461539,24.013076923076927,25.341538461538466,{"y":26.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.4,9.6,9.8,10,10.200000000000001,10.4,10.6,10.8,11,11.2,11.4,11.6,11.8,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.09,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.71,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.11,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >